Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

20studies shown

Showing 1-12 of 20

Drug study icon

RecruitingNCT06929273

KarXT for manic episodes in bipolarity type I

The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in France, ...

In New Zealand

BipolarityDrugFrom 18 Years to 65 Years

Countries: United States, Australia, France, ...
Sponsor: Bristol-Myers Squibb
Condition: Bipolarity

Drug study icon

RecruitingNCT06951698

KarXT for manic episodes in bipolarity type I

The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in New Zealand, ...

In New Zealand

BipolarityDrugFrom 18 Years to 65 Years

Countries: United States, Australia, New Zealand, ...
Sponsor: Bristol-Myers Squibb
Condition: Bipolarity

Other study type icon

RecruitingNCT06579950

Assessing the Effects of Cool Roofs on Indoor Environments and Health

This summary needs review. Please check the official study record and contact the research team for details.

Broader result

DepressionOtherOver 18 Years

Countries: New Zealand, Burkina Faso, Fiji, ...
Sponsor: Aditi Bunker
Condition: Depression

Behavioral study icon

RecruitingNCT06594913

Eating disorders Genetics Initiative 2

This summary needs review. Please check the official study record and contact the research team for details.

In New Zealand

Eating disordersBehavioralFrom 12 Years to 99 Years

Countries: United States, Australia, New Zealand, ...
Sponsor: University of North Carolina, Chapel Hill
Condition: Eating disorders

Drug study icon

TerminatedNCT01568216

20101299: Study Effect of AMG 747 on Schizophrenia Negative Symptoms

This study was terminated in the United States, in Australia, in Canada, .... It focuses on schizophrenia.

In New Zealand

SchizophreniaDrugFrom 18 Years to 60 Years

Countries: United States, Australia, Canada, ...
Sponsor: Amgen
Condition: Schizophrenia

Drug study icon

CompletedNCT01051531

A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to people with Schizophrenia

This study is completed in Australia, in New Zealand, in China, .... It focuses on schizophrenia.

In New Zealand

SchizophreniaDrugFrom 18 Years to 50 Years

Countries: Australia, New Zealand, China, ...
Sponsor: Janssen Research & Development, LLC
Condition: Schizophrenia

Drug study icon

TerminatedNCT05211947

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

This study was terminated in the United States, in Australia, in France, .... It focuses on schizophrenia.

In New Zealand

SchizophreniaDrugFrom 18 Years to 51 Years

Countries: United States, Australia, France, ...
Sponsor: Boehringer Ingelheim
Condition: Schizophrenia

Drug study icon

CompletedNCT04895215

AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)

This summary needs review. Please check the official study record and contact the research team for details.

In New Zealand

AnxietyDrugFrom 5 Years to 17 Years

Countries: United States, Australia, New Zealand
Sponsor: Vertero Therapeutics
Condition: Anxiety

Behavioral study icon

CompletedNCT06570993

Assessing the Effects of Cool Roofs on Indoor Environments and Health in Niue

This summary needs review. Please check the official study record and contact the research team for details.

Broader result

DepressionBehavioralOver 18 Years

Countries: New Zealand
Sponsor: Aditi Bunker
Condition: Depression

Other study type icon

CompletedNCT03700112

Clinical Study Comparing 7 ENDS Products and 1 Combustible Cigarette Using 2 Delivery Methods.

This summary needs review. Please check the official study record and contact the research team for details.

In New Zealand

AddictionOtherFrom 18 Years to 60 Years

Countries: New Zealand
Sponsor: Juul Labs, Inc.
Condition: Addiction

Drug study icon

CompletedNCT04846868

study of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

This summary needs review. Please check the official study record and contact the research team for details.

In New Zealand

SchizophreniaDrugFrom 18 Years to 50 Years

Countries: United States, Australia, Canada, ...
Sponsor: Boehringer Ingelheim
Condition: Schizophrenia

Other study type icon

CompletedNCT03593239

Comparing the Pharmacokinetics of Nicotine Salt Based ENDS in Healthy Smokers

This summary needs review. Please check the official study record and contact the research team for details.

In New Zealand

AddictionOtherFrom 18 Years to 60 Years

Countries: New Zealand
Sponsor: Juul Labs, Inc.
Condition: Addiction

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.